Pfizer (United States)
Papers in the tracked journals with an author at Pfizer (United States): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.
Key findings#
- From 2017 to 2026 (so far), authors at Pfizer (United States) took part in 40 papers in the tracked journals, most of them in health economics and policy (37), economics (1) and statistics (1).
- 3 of them were published in 2025, against 3 in 2017.
- Since 2023, the institutions with the most of these papers were Pfizer (United Kingdom) (6), Merck Healthcare KGaA, Darmstadt (Germany) (2) and Nemours Children's Health System (2).
- The journals publishing most of them were PharmacoEconomics - Open (6), PharmacoEconomics (5) and Cost Effectiveness and Resource Allocation (5).
- The most-cited of them is “Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment” (PharmacoEconomics, 2020), with 101 citations.
Papers per year#
20172026 (so far)
| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---|---|---|---|---|---|---|---|---|---|
| Health Economics and Policy | 2 | 1 | 3 | 4 | 7 | 2 | 4 | 6 | 3 | 5 |
| Economics | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Statistics | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Finance | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| All categories | 3 | 1 | 3 | 5 | 8 | 2 | 4 | 6 | 3 | 5 |
Where the papers come from#
| # | Journal | Papers |
|---|---|---|
| 1 | PharmacoEconomics - Open | 6 |
| 2 | PharmacoEconomics | 5 |
| 3 | Cost Effectiveness and Resource Allocation | 5 |
| 4 | Applied Health Economics and Health Policy | 1 |
| 5 | The European Journal of Health Economics | 1 |
| # | Institution | Papers |
|---|---|---|
| 1 | Pfizer (United Kingdom) | 6 |
| 2 | Merck Healthcare KGaA, Darmstadt (Germany) | 2 |
| 3 | Nemours Children's Health System | 2 |
| 4 | AbbVie (United Kingdom) | 1 |
| 5 | Astellas Pharma (United States) | 1 |
| 6 | Carelon Research (United States) | 1 |
| 7 | GlaxoSmithKline (United States) | 1 |
| 8 | Guy's and St Thomas' NHS Foundation Trust | 1 |
| 9 | Health Economics and Outcomes Research (United Kingdom) | 1 |
| # | Country | Papers |
|---|---|---|
| 1 | United States | 18 |
| 2 | United Kingdom | 8 |
| 3 | Germany | 3 |
| 4 | Australia | 1 |
| 5 | Canada | 1 |
| 6 | Switzerland | 1 |
| 7 | Colombia | 1 |
| 8 | Ireland | 1 |
| 9 | Sweden | 1 |
| # | Keyword | Papers |
|---|---|---|
| 1 | quality-adjusted life years | 6 |
| 2 | cost-effectiveness | 5 |
| 3 | PCV20 | 3 |
| 4 | economic burden | 3 |
| 5 | first-line therapy | 3 |
| 6 | health technology assessment | 3 |
| 7 | health-related quality of life | 3 |
| 8 | healthcare resource utilization | 3 |
| 9 | 23-valent pneumococcal polysaccharide vaccine | 2 |
| 10 | Duchenne muscular dystrophy | 2 |
Most-cited papers#
Cite this page
Scholar4AI. (2026). Pfizer (United States). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/pfizer-united-states
@misc{scholar4ai-companies-pfizer-united-states,
author = {{Scholar4AI}},
title = {Pfizer (United States)},
year = {2026},
howpublished = {\url{https://scholar4ai.com/companies/pfizer-united-states}},
urldate = {2026-10-31},
note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}